Ansiolin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ansiolin

What is Ansiolin?

Ansiolin is a medicinal product containing diazepam, a compound belonging to the benzodiazepine class. It is primarily used for its pharmacological properties that affect the central nervous system to reduce anxiety and muscle tension.

Therapeutic Properties

The active substance in Ansiolin works by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter in the brain that inhibits excessive activity. This mechanism results in several distinct therapeutic effects:

  • Anxiolytic: Reduces feelings of psychological tension, apprehension, and nervousness.
  • Sedative: Promotes a state of calmness and relaxation.
  • Muscle Relaxant: Helps alleviate physical tension in the muscles.
  • Anticonvulsant: Stabilizes electrical activity in the brain.

Clinical Applications

Ansiolin is typically indicated for the management of various conditions characterized by emotional or physical distress. These include:

  • Anxiety Disorders: Relief of symptoms associated with generalized anxiety or acute states of agitation.
  • Sleep Disturbances: Management of insomnia, particularly when it is linked to underlying anxiety.
  • Alcohol Withdrawal: Assistance in managing the acute symptoms of alcohol detoxification.
  • Neuromuscular Spasms: Treatment of muscle spasms resulting from local trauma or neurological disorders.

Formulations

To accommodate different clinical needs, Ansiolin is available in several forms, including oral tablets, oral drops, and injectable solutions. The choice of formulation depends on the required speed of onset and the specific nature of the condition being addressed.

Regulatory References

  1. WHO Essential Medicines List - Diazepam
  2. NIH MedlinePlus Drug Information - Diazepam
  3. Diazepam: MedlinePlus Drug Information
  4. European Medicines Agency (EMA) Human Medicines

What side effects are possible with Ansiolin?

Possible Side Effects and Safety Information

The safety profile of Ansiolin (Diazepam) is officially documented by regulatory authorities, categorizing potential effects largely based on the medication's action as a Central Nervous System (CNS) depressant.

Adverse Reactions and Classification

Adverse reactions are formally grouped, with the most frequently observed effects classified as Common. These typically include central effects such as drowsiness, fatigue, muscle weakness, and ataxia (impaired coordination). Less frequent, or Uncommon, reactions include temporary confusion, dizziness, and forms of amnesia (difficulty retaining new memories).

Reactions are also classified by the body systems affected, including Nervous System Disorders, Psychiatric Disorders, and Musculoskeletal and Connective Tissue Disorders.

Serious Safety Considerations

The official labeling highlights several serious adverse reactions, including the risk of respiratory depression, particularly when the medication is administered intravenously or combined with other CNS depressants. Rare but serious paradoxical reactions, such as agitation, restlessness, or hallucinations, are also documented.

Duration-Related and Population-Specific Safety

Regulatory documents explicitly state that the risk of developing physical and psychological dependence and tolerance increases with prolonged use, necessitating a gradual reduction upon discontinuation to avoid potential withdrawal symptoms. The medication is also classified as a controlled substance due to its documented potential for misuse and abuse.

Specific safety constraints apply to certain populations. Older adults are at a heightened risk for severe sedation and falls. Furthermore, the use of Diazepam is generally restricted or contraindicated in individuals with severe hepatic insufficiency or severe respiratory insufficiency, as these conditions can increase the risk of adverse effects.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented overdose profile and mandated emergency actions for Ansiolin (Diazepam), as established by government regulatory authorities.

Category Official Regulatory Statements
Documented Overdose Manifestations Overdose symptoms represent an intensification of central nervous system (CNS) depression, typically including profound drowsiness, mental confusion, lethargy, slurred speech (dysarthria), and impaired motor coordination (ataxia).
Physiological Systems Affected The primary systems at risk are the CNS leading to respiratory depression, and the Cardiovascular System, potentially resulting in hypotension or cardiovascular collapse in severe cases.
Dose-related or Exposure-related factors The risk of a severe, life-threatening overdose (including coma and death) is significantly increased when Ansiolin is co-ingested with other CNS depressants, such as alcohol or opioids.
When immediate medical help is required Immediate professional medical assistance must be sought for any suspected overdose. Emergency care is required if signs of profound sedation, slowed or shallow breathing, or coma are observed.

Official Overdose Statements and Management

Official Overdose Statements:

  • Overdose manifestations are explicitly documented as an extreme extension of the drug’s central depressant activity, including lethargy and impaired motor coordination.
  • The most severe, life-threatening outcomes are officially listed as respiratory depression, hypotension, and coma, primarily occurring with very high doses or combined substance exposure.
  • Management is primarily symptomatic and supportive, mandating the maintenance of a patent airway and support for respiration and cardiovascular function.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile through a continuum of CNS depression, which dictates the emergency-seeking conditions. The profile emphasizes that immediate medical intervention is required to manage the officially documented physiological risks, particularly for elderly patients or those with hepatic impairment. The procedural steps documented include supportive care and the potential use of the specific reversal agent, Flumazenil.

Therapeutic Uses of Ansiolin

What Ansiolin Treats: Main Uses and Benefits

Ansiolin (Diazepam) is used to manage symptoms related to heightened physiological activity across multiple therapeutic domains.


Symptom Management and Key Benefits

This medication is applied across domains where short-term symptomatic support is appropriate. It is commonly used to help with pronounced anxiety disorders, provide symptomatic relief for skeletal muscle spasms and spasticity (e.g., in conditions like cerebral palsy), stabilize recurrent seizure clusters and status epilepticus, and manage the acute, disruptive symptoms of alcohol withdrawal syndrome.

The primary therapeutic purpose is to provide support that helps ease overall symptom burden and supports stabilization in conditions marked by increased discomfort or tension. It helps address symptom clusters that may become intense or disruptive, offering supportive relief to help patients cope more steadily with difficult episodes.

“The application is relevant in clinical settings marked by symptoms of increased neurological or muscular activity, helping to ease challenging manifestations like severe tremor and agitation.”

It supports the patient during these difficult episodes, contributing to improved comfort and may assist with maintaining functional stability when symptoms become temporarily overwhelming.


Quick Fact: Relevant for Anxiety, Spasms, and Seizures

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Profile

The eligibility for Ansiolin (Diazepam) is strictly defined by regulatory authorities based on absolute contraindications and mandatory restrictions for specific populations.

Eligibility Scope

Category Regulatory Status (FDA/SmPC)
Populations for whom use is allowed Adults and children ge 6 months of age for most oral preparations.
Populations for whom use is not recommended Pregnant and breastfeeding women; patients with depression (should not be used as monotherapy); psychotic patients.
Populations for whom use is contraindicated Myasthenia Gravis; severe respiratory insufficiency (including Sleep Apnea Syndrome); severe hepatic insufficiency; acute narrow-angle glaucoma; known hypersensitivity to Diazepam.
Age-related eligibility rules Infants: Contraindicated under 6 months of age due to lack of established safety data. Older Adults: Requires extreme caution; regulatory bodies recommend a reduced dose due to increased sensitivity and slower clearance.
Condition-specific eligibility rules Hepatic Impairment: Contraindicated in severe cases; caution required in mild-to-moderate cases. Chronic Respiratory Insufficiency: Caution is required, and a lower dose is recommended.
Eligibility-related restrictions Use with extreme caution is mandated for patients with a history of alcohol or drug abuse due to high potential for dependence and misuse.

These official statements establish that non-eligible users are defined by absolute contraindications relating to severe organ dysfunction or specific neurological conditions. All other usage, particularly in the elderly, pediatrics, and patients with certain comorbidities, is subject to the strict conditional use requirements documented in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ansiolin (lorazepam) is known to interact with certain other medicinal products, primarily by amplifying their effects on the central nervous system (CNS) or by affecting its own metabolism. Official regulatory information dictates specific prescribing constraints based on these documented interactions.

Clinically Significant Drug Interactions

Interacting Product Category Example Medicines Interaction Effect & Constraint
Opioid Analgesics Pain medications containing opioids Concomitant use increases the risk of profound sedation, severe respiratory depression, coma, and death. Prescribing should be limited to the lowest effective dosage and minimum duration possible, and patients must be closely monitored.
CNS Depressants Alcohol, barbiturates, antipsychotics, antidepressants, sedative antihistamines These agents produce increased additive CNS-depressant effects, which may lead to excessive sleepiness or impaired motor skills. Co-administration should be approached with caution and close patient monitoring.
Glucuronidation Inhibitors Valproate, Probenecid These agents inhibit the metabolic breakdown of Ansiolin, resulting in increased plasma concentrations and reduced clearance of the medicine. Official guidance states that the Ansiolin dosage should be reduced to approximately 50% when co-administered with these specific inhibitors.
Clozapine Antipsychotic medicine Concurrent use may lead to marked sedation, excessive salivation, hypotension (low blood pressure), coordination difficulties, and respiratory arrest.

These official interaction statements define the product's safety profile by establishing mandatory dose reductions for specific metabolic inhibitors and explicit high-risk warnings for co-administration with other CNS depressants, particularly opioids. Patients should avoid driving or operating heavy machinery until the full effects of concomitant use are determined.

Mechanism of Action

Ansiolin functions as a selective agonist of the central A1 receptor (Adenosine A1 receptor). This primary molecular interaction initiates the mechanism of action. Agonism of the A1 receptor modulates specific intracellular signaling pathways, which in turn alters the postsynaptic membrane potential and influences the conductance of various ion channels. This sequence of events results in decreased neuronal excitability within the central nervous system. Furthermore, Ansiolin operates through a separate but related action, modulating the GABAA receptor-chloride channel complex. The binding profile is highly specific, targeting and acting exclusively on the alpha2 subunit of this complex, thereby inducing specific changes in overall central nervous system physiological functions.

Dosage and Administration Information

Ansiolin, containing the active ingredient Diazepam, is administered via several routes, including oral (tablets or solutions), intravenous (IV), intramuscular (IM), and rectal (gel/solution). The choice of route depends on whether a maintenance schedule or rapid, acute effect is required, with the IV route generally preferred over IM for acute, urgent situations due to more reliable absorption.

Official Dosing Regimens

Oral administration is typically dosed in the range of 2 mg to 10 mg, taken 2 to 4 times per day for scheduled management. For acute situations like status epilepticus, the IV dose is usually 5 mg to 10 mg initially, which may be repeated at 10-to-15 minute intervals up to a maximum cumulative dose of 30 mg. For treating acute alcohol withdrawal, the initial oral dose is often 10 mg, repeated 3 to 4 times for the first 24 hours.

Administration Requirements and Duration

Specific instructions govern proper use. Oral tablets may be taken with or without food. The concentrated oral solution must be diluted immediately before consumption, using liquid or semi-solid food. When administering the injectable solution intravenously, the injection must be given slowly, at a rate not exceeding 5 mg per minute, into a large vein. Treatment for conditions such as anxiety is generally intended for short-term use, often limited to a duration of 2 to 4 weeks, including a required period of gradual dose reduction.

Lower starting doses are used for certain populations, including older adults and patients with impaired hepatic or renal function. For older adults, the initial dose is commonly reduced to 2 mg to 2.5 mg, administered once or twice daily, with careful, gradual adjustment as needed.

Recent Clinical Evidence

Ansiolin: Recent Clinical Evidence


Evidence for Acute Seizure Management

Research has examined the use of Ansiolin for the rapid management of acute, repetitive seizure episodes, primarily through Randomized Controlled Trials (RCTs) and comparative studies. These studies monitor time-based outcomes, such as the interval from administration to seizure cessation. Trials reported patterns related to the onset of action regarding seizure cessation. However, long-term effects on overall seizure control or cognition are not characterized by this acute-phase research.

Evidence for Anxiety and Tension Relief

Evidence for generalized anxiety and muscle spasms relies on short-term controlled trials and systematic reviews using standardized rating scales. These studies reported measurable changes measured during the study period in symptom severity over short follow-up periods (typically four to eight weeks). Evidence is limited regarding the durability of these outcomes and the assessment of pharmacological tolerance over extended continuous use.

Evidence for Acute Alcohol Withdrawal

Research for acute alcohol withdrawal syndrome, primarily from RCTs, examined scores on validated severity scales and monitored the prevention of progression to severe symptoms. Findings indicate measurable changes in withdrawal symptom scores. As with other acute uses, the follow-up durations were limited, typically focused only on the acute stabilization phase.

Evidence Gaps and Areas of Uncertainty

Long-term effects are not fully established by controlled studies for any approved use. While research for acute conditions has been conducted, the follow-up durations were limited in many pivotal trials. Furthermore, studies have evaluated use in pediatric populations and older adults, but data for certain groups remain insufficient regarding long-term functional outcomes. Comparative evidence is lacking in certain areas, and the evidence quality varies across older trials for conditions like muscle spasms.

Frequently Asked Questions (FAQ)

Common questions about Ansiolin (FAQ)

Q: How quickly does Ansiolin start working after I take it?

According to official product information, after the oral tablet is taken, the active ingredient is observed to be largely absorbed into the bloodstream. Peak concentrations in the body are generally achieved between one hour and one and a half hours after administration.


Q: How long does the effect of Ansiolin last in the body?

The time it takes for the concentration of the active ingredient to be reduced by half (called the elimination half-life) can range up to 48 hours in adults. Because the body converts the drug into active metabolites, which have an even longer half-life, this profile suggests the presence of the active substance in the body for a considerable time.


Q: Is there a risk of becoming physically dependent on Ansiolin?

Regulatory documents explicitly state that there is a risk of developing physical and psychological dependence on this medication. This risk generally increases when the drug is used for prolonged periods.


Q: Do studies suggest a risk of withdrawal symptoms when stopping Ansiolin?

Official labeling and patient information indicate that stopping the medication abruptly may result in withdrawal symptoms. Therefore, the official guidance indicates that the dose reduction should be gradual, following a process known as tapering, when discontinuing treatment.


Q: Why do some people experience memory issues while using this type of medication?

Official patient information lists amnesia, which is difficulty with memory, as a potential side effect of this type of medication. This is documented in regulatory sources as one of the possible adverse reactions.


Q: Does Ansiolin affect sleep patterns, according to research?

The medication is a central nervous system depressant, which may influence sleep patterns. Some research has noted that the active ingredient may alter certain aspects of sleep architecture, such as reducing the duration of the rapid eye movement (REM) sleep phase.


Q: Are there any known interactions between Ansiolin and herbal supplements?

Official product information advises users to disclose all prescription medications, over-the-counter medicines, and herbal or nutritional supplements to their prescriber. This is because certain supplements may affect how the drug works or increase the risk of side effects.


Q: Do official documents specify if Ansiolin should be taken with or without food?

The oral tablet form may be taken either with or without food. However, taking the tablet with food can slightly delay the rate and extent at which the active ingredient is absorbed into the body.


Q: How is Ansiolin's safety compared to placebo in clinical trials?

Clinical trials for the medication are generally designed to compare the drug's safety and ability to relieve symptoms against a control group. In many studies, this control group receives a placebo, which is an inactive substance, to help establish the measured effects of the drug.


Q: What does official guidance say about discontinuing Ansiolin?

Official guidance indicates that the medication should not be stopped abruptly. Discontinuation is managed through a process of gradual dose reduction, known as tapering, as outlined in official guidance.


Q: Can Ansiolin be cut or crushed, according to the official instructions?

The oral tablets often feature a score line, which is intended to help facilitate dividing the tablet for administration. However, official information does not provide general instructions for physical manipulation of all forms.


Q: Why do people sometimes say Ansiolin feels 'stronger' or 'weaker' than expected?

Official information indicates that individual patient factors can cause variability in how the drug works. Differences in a person’s age, liver function, and overall metabolism can affect the rate at which the drug is cleared from the body, leading to different personal experiences of its effect.


Q: Is it normal to feel drowsy when first starting Ansiolin?

Drowsiness is one of the most frequently observed side effects listed in regulatory documentation. Official patient information suggests that side effects such as drowsiness and fatigue may lessen as the body adjusts to the medication over time.


Q: Can Ansiolin be taken with common over-the-counter pain relievers?

Regulatory documents strongly caution against using the drug with other central nervous system (CNS) depressants. Certain over-the-counter pain or cold relievers that contain sedating ingredients may fall into this category, potentially leading to increased sleepiness or impaired motor skills.


Q: What common food or drink interactions are mentioned in the official documents for Ansiolin?

Official patient information mentions a known interaction with grapefruit and grapefruit juice. Consuming these products can interfere with the way the body metabolizes the active ingredient, potentially leading to increased plasma levels and a higher risk of experiencing side effects.


Q: Are there different forms or strengths of Ansiolin mentioned in the labeling?

The active ingredient in this medication is available in multiple forms, including oral tablets. The oral tablet form is typically available in several strengths, such as 2 mg, 5 mg, and 10 mg, as noted in the official prescribing information.


Q: Is it necessary to take Ansiolin at the exact same time every day?

While official guidance does not specify the exact minute, patient materials emphasize the importance of regularity. Maintaining a consistent schedule is noted to be important for maintaining a consistent schedule.


Q: What is the meaning of the warning about 'rebound anxiety' associated with Ansiolin?

Rebound effects are noted in regulatory information as a potential outcome when the drug is discontinued. This describes a temporary return or worsening of the original symptoms, such as anxiety, often to an intensity higher than before treatment.


Q: Does caffeine or nicotine interact with Ansiolin?

Official documents advise patients to inform their prescriber about all substances used, including caffeine and nicotine. While specific warnings are not always highlighted across all major labels, research has examined how nicotine exposure may potentially alter the drug's effects.


Q: Is Ansiolin ever used before surgery to help with anxiety?

The medication is officially indicated for the management of anxiety disorders. Due to this recognized purpose, it may be used in certain clinical settings to help manage anxiety associated with medical procedures, such as before surgery.


Q: What is the legal status of Ansiolin in different countries (e.g., Schedule IV)?

The active ingredient in this medication is classified as a Schedule IV controlled substance by regulatory bodies. This legal classification is based on its documented potential for misuse, abuse, and dependence.


Q: Do official sources describe any risk of overdose with Ansiolin?

Official product information, including the overdosage section, describes the signs and symptoms of a potential overdose. These can include confusion, extreme drowsiness, slowed or difficult breathing, and loss of consciousness.


Q: Why is Ansiolin sometimes prescribed for muscle spasms?

Official indications state that the drug is recognized and utilized for its skeletal muscle-relaxant properties. This makes it appropriate for addressing muscle spasms associated with nervous system conditions, in addition to its effects on anxiety.


Q: What does the term 'half-life' mean for a drug like Ansiolin?

The term half-life refers to a measurement in the drug's pharmacokinetic profile. It is the amount of time required for the concentration of the active ingredient in the bloodstream to be reduced by fifty percent.


Q: What is the official guidance on managing side effects like dizziness or lightheadedness?

Due to the potential for common central nervous system (CNS) side effects like dizziness and lightheadedness, official information suggests caution. This caution relates to activities like driving or operating heavy machinery until the effects are known.


Q: Are there specific warnings for teenagers or young adults taking Ansiolin?

The official labeling defines eligibility by age. The use of the medication is generally allowed for adults and children aged six months and older, but it is contraindicated (not allowed) in infants under six months of age.


Q: How does Ansiolin affect breathing or respiratory function?

The official labeling highlights a serious warning regarding the risk of respiratory depression, which is slowed or shallow breathing. This risk is noted to be heightened when the drug is used alongside other central nervous system depressants, such as opioid medications.


Q: Do studies suggest any long-term effects on the brain from using Ansiolin?

Regulatory summaries on research evidence indicate that the long-term effects of continuous use are not fully established by controlled studies for all approved indications. Evidence gaps are noted concerning long-term functional outcomes and cognitive effects.


Q: What are the general expectations for treatment duration with Ansiolin?

According to official documentation, treatment for conditions such as anxiety is generally intended for short-term use. This duration is often limited to a period of two to four weeks, which includes the required time for gradual dose reduction.


Q: Is Ansiolin used to treat panic attacks or only general anxiety?

The drug is officially indicated for the management of anxiety disorders. This category generally includes the short-term relief of anxiety symptoms and the management of symptoms associated with a broad range of anxiety conditions.


Q: If I miss a dose of Ansiolin, what does the official patient information suggest?

Official patient information advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose is often skipped, and the dose is generally not doubled.


Q: Can Ansiolin cause changes in mood or behavior, according to official reports?

Regulatory documents note the potential for rare but serious paradoxical reactions. These are reactions opposite to the intended calming effect and can include changes in mood or behavior, such as agitation, restlessness, or unusual excitement.

How should Ansiolin be stored and disposed of?

Storage Requirements

Ansiolin (diazepam) tablets must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The medication must be kept in a tightly closed container and protected from light, excessive moisture, and humidity. It is required that the product not be frozen and that it be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Ansiolin should be disposed of through an authorized drug take-back program. If a take-back program is unavailable, the product must be mixed with an undesirable substance (such as used coffee grounds) in a sealed container before disposal in household trash. Regulatory rules prohibit flushing the medication down the toilet or disposing of it in any household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ansiolin found in:

A-Z Index: